These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 18797822)
1. Impact of 111In-DTPA-octreotide SPECT/CT fusion images in the management of neuroendocrine tumours. Castaldi P; Rufini V; Treglia G; Bruno I; Perotti G; Stifano G; Barbaro B; Giordano A Radiol Med; 2008 Oct; 113(7):1056-67. PubMed ID: 18797822 [TBL] [Abstract][Full Text] [Related]
2. Image fusion analysis of (99m)Tc-HYNIC-Tyr(3)-octreotide SPECT and diagnostic CT using an immobilisation device with external markers in patients with endocrine tumours. Gabriel M; Hausler F; Bale R; Moncayo R; Decristoforo C; Kovacs P; Virgolini I Eur J Nucl Med Mol Imaging; 2005 Dec; 32(12):1440-51. PubMed ID: 16133384 [TBL] [Abstract][Full Text] [Related]
3. Octreo-SPECT/CT imaging for accurate detection and localization of suspected neuroendocrine tumors. Perri M; Erba P; Volterrani D; Lazzeri E; Boni G; Grosso M; Mariani G Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):323-33. PubMed ID: 18480741 [TBL] [Abstract][Full Text] [Related]
4. Value of image fusion using single photon emission computed tomography with integrated low dose computed tomography in comparison with a retrospective voxel-based method in neuroendocrine tumours. Amthauer H; Denecke T; Rohlfing T; Ruf J; Böhmig M; Gutberlet M; Plöckinger U; Felix R; Lemke AJ Eur Radiol; 2005 Jul; 15(7):1456-62. PubMed ID: 15627182 [TBL] [Abstract][Full Text] [Related]
5. Incremental value of Trogrlic M; Težak S Nuklearmedizin; 2017 Jun; 56(3):97-107. PubMed ID: 28164207 [TBL] [Abstract][Full Text] [Related]
6. Benefit of anatomical-functional image fusion in the diagnostic work-up of neuroendocrine neoplasms. Pfannenberg AC; Eschmann SM; Horger M; Lamberts R; Vonthein R; Claussen CD; Bares R Eur J Nucl Med Mol Imaging; 2003 Jun; 30(6):835-43. PubMed ID: 12682789 [TBL] [Abstract][Full Text] [Related]
7. 64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients. Pfeifer A; Knigge U; Binderup T; Mortensen J; Oturai P; Loft A; Berthelsen AK; Langer SW; Rasmussen P; Elema D; von Benzon E; Højgaard L; Kjaer A J Nucl Med; 2015 Jun; 56(6):847-54. PubMed ID: 25952736 [TBL] [Abstract][Full Text] [Related]
8. Localization of neuroendocrine tumours with [111In] DTPA-octreotide scintigraphy (Octreoscan): a comparative study with CT and MR imaging. Shi W; Johnston CF; Buchanan KD; Ferguson WR; Laird JD; Crothers JG; McIlrath EM QJM; 1998 Apr; 91(4):295-301. PubMed ID: 9666953 [TBL] [Abstract][Full Text] [Related]
10. Attenuation correction of somatostatin receptor SPECT by integrated low-dose CT: is there an impact on sensitivity? Steffen IG; Mehl S; Heuck F; Elgeti F; Furth C; Amthauer H; Ruf J Clin Nucl Med; 2009 Dec; 34(12):869-73. PubMed ID: 20139819 [TBL] [Abstract][Full Text] [Related]
11. Localization of neuroendocrine tumours and insulinomas using radiolabelled somatostatin analogues, 123I-Tyr3-octreotide and 111In-pentatreotide. Ur E; Bomanji J; Mather SJ; Britton KE; Wass JA; Grossman AB; Besser GM Clin Endocrinol (Oxf); 1993 May; 38(5):501-6. PubMed ID: 8101146 [TBL] [Abstract][Full Text] [Related]
12. Comparison of diagnostic accuracy of (111)In-pentetreotide SPECT and (68)Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours. Van Binnebeek S; Vanbilloen B; Baete K; Terwinghe C; Koole M; Mottaghy FM; Clement PM; Mortelmans L; Bogaerts K; Haustermans K; Nackaerts K; Van Cutsem E; Verslype C; Verbruggen A; Deroose CM Eur Radiol; 2016 Mar; 26(3):900-9. PubMed ID: 26162577 [TBL] [Abstract][Full Text] [Related]
13. Physiological Uptake in the Pancreatic Head on Somatostatin Receptor Scintigraphy Using [111In-DTPA]Octreotide: Incidence and Mechanism. Brabander T; Teunissen J; Kwekkeboom D Clin Nucl Med; 2017 Jan; 42(1):15-19. PubMed ID: 27775943 [TBL] [Abstract][Full Text] [Related]
14. Contribution of ¹¹¹In-pentetreotide SPECT/CT imaging to conventional somatostatin receptor scintigraphy in the detection of neuroendocrine tumours. Sainz-Esteban A; Olmos R; González-Sagrado M; González ML; Ruiz MÁ; García-Talavera P; Gamazo C; Villanueva JG; Cobo A; de Luis D Nucl Med Commun; 2015 Mar; 36(3):251-9. PubMed ID: 25369750 [TBL] [Abstract][Full Text] [Related]
15. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. Srirajaskanthan R; Kayani I; Quigley AM; Soh J; Caplin ME; Bomanji J J Nucl Med; 2010 Jun; 51(6):875-82. PubMed ID: 20484441 [TBL] [Abstract][Full Text] [Related]
16. Thoracic and abdominal SPECT-CT image fusion without external markers in endocrine carcinomas. The Group of Thyroid Tumoral Pathology of Champagne-Ardenne. Pérault C; Schvartz C; Wampach H; Liehn JC; Delisle MJ J Nucl Med; 1997 Aug; 38(8):1234-42. PubMed ID: 9255157 [TBL] [Abstract][Full Text] [Related]
17. Feasibility of a streamlined imaging protocol in technetium-99m-Tektrotyd somatostatin receptor SPECT/CT. Al-Chalabi H; Cook A; Ellis C; Patel CN; Scarsbrook AF Clin Radiol; 2018 Jun; 73(6):527-534. PubMed ID: 29397911 [TBL] [Abstract][Full Text] [Related]
18. Uptake in the pancreatic uncinate process on the 111In-octreotide scintigraphy: How to distinguish physiological from pathological uptake? Ait Boudaoud A; Verges B; Petit JM; Tatulashvili S; Cochet A; Humbert O Nucl Med Commun; 2017 Sep; 38(9):737-743. PubMed ID: 28704340 [TBL] [Abstract][Full Text] [Related]
19. Radiolabeled somatostatin analog scintigraphy in oncology and immune diseases: an overview. Kwekkeboom DJ; Krenning EP Eur Radiol; 1997; 7(7):1103-9. PubMed ID: 9265684 [TBL] [Abstract][Full Text] [Related]
20. Somatostatin receptor scintigraphy of carcinoid tumours using the [111In-DTPA-D-Phe1]-octreotide. Westlin JE; Janson ET; Arnberg H; Ahlström H; Oberg K; Nilsson S Acta Oncol; 1993; 32(7-8):783-6. PubMed ID: 8305227 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]